← Back to Search
2DG Enhances The Susceptibility Of Breast Cancer Cells To Doxorubicin
I. Ahmad, Ebtihal H. Mustafa, N. Mustafa, L. Tahtamouni, M. Y. Abdalla
Published 2010 · Biology
Save to my Library
Download PDFAnalyze on Scholarcy
Abstract2DG causes cytotoxicity in cancer cells by disrupting thiol metabolism while Doxorubicin (DOX) induces cytotoxicity in tumor cells by generating reactive oxygen species (ROS). Here we examined the combined cytotoxic action of 2DG and DOX in rapidly dividing T47D breast cancer cells vs. slowly growing MCF-7 breast cancer cells. T47D cells exposed to the combination of 2DG/DOX significantly decreased cell survival compared to controls, while 2DG/DOX had no effect on MCF-7 cells. 2DG/DOX also disrupted the oxidant status of T47D treated cells, decreased intracellular total glutathione and increased glutathione disulfide (%GSSG) compared to MCF-7 cells. Lipid peroxidation increased in T47D cells treated with 2DG and/or DOX, but not in MCF-7 cells. T47D cells were significantly protected by NAC, indicating that the combined treatment exerts its action by increasing ROS production and disrupting antioxidant stores. When we inhibited glutathione synthesis with BSO, T47D cells became more sensitive to 2DG/DOX-induced cytotoxicity, but NAC significantly reversed this cytotoxic effect. Finally, 2DG/DOX, and BSO significantly increased the %GSSG in T47D cells, an effect which was also reversed by NAC. Our results suggest that exposure of rapidly dividing breast cancer cells to 2DG/DOX enhances cytotoxicity via oxidative stress and via disruptions to thiol metabolism.
This paper references
The effect of in vivo glutathione depletion with buthionine sulfoximine on rat embryo development.
B. Hales (1991)
A novel model of continuous depletion of glutathione in mice treated with L-buthionine (S,R)-sulfoximine.
T. Watanabe (2003)
Localization of the primary metabolic block produced by 2-deoxyglucose.
A. N. Wick (1957)
Adriamycin metabolism in man. Evidence from urinary metabolites.
S. Takanashi (1976)
Non-nitro radiation sensitizers.
M. A. Shenoy (1985)
An overview of fifty years in cancer research: autobiographical essay.
A. Goldfeder (1976)
[Origin of cancer cells].
O. Warburg (1956)
2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress.
I. Ahmad (2008)
Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-D-glucose.
K. Kern (1987)
2-Deoxy-D-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers
G. Maschek (2004)
Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation.
N. Aykin-Burns (2009)
Improving cancer radiotherapy with 2deoxy: phase I / II clinical trials on human cerebral gliomas
K. MohantiB. (2006)
Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism.
David M Mattson (2009)
2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism.
Xiao Lin (2003)
Adriamycin Metabolism in Man
N. Bachur (1976)
Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine.
O. Griffith (1980)
buthionine sulfoximine : historical development and clinical issues
H. BaileyH. (2002)
2-Deoxyglucose as a substrate for glutathione regeneration in human and ruminant red blood cells.
M. Suzuki (1983)
Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity.
L. Gille (1997)
Glucose Deprivation-induced Cytotoxicity and Alterations in Mitogen-activated Protein Kinase Activation Are Mediated by Oxidative Stress in Multidrug-resistant Human Breast Carcinoma Cells*
Y. J. Lee (1998)
Antioxidant inhibitors for cancer therapy.
Q. Kong (1998)
Antioxidant nutrients and adriamycin toxicity.
J. Quiles (2002)
Oxidative stress: damage to intact cells and organs.
H. Sies (1985)
Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
A. K. Tyagi (2002)
Animal Responses to 2-Deoxy-D-Glucose Administration
B. Landau (1958)
 Oxygen electrode
D. C. Fork (1972)
Aerobic glycolysis during lymphocyte proliferation
T. Wang (1976)
Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple.
F. Q. Schafer (2001)
Hypoglycemia-induced AP-1 transcription factor and basic fibroblast growth factor gene expression in multidrug resistant human breast carcinoma MCF-7/ADR cells
S. Galoforo (2004)
COMET OBSERVATIONS AT PRINCETON.
C. A. Young (1881)
2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells.
A. L. Simons (2007)
2-deoxyglucose as a substrate for glutathione regeneration in human and ruminant red blood 747 2DG enhances the susceptibility of breast cancer cells to doxorubicin
M. Suzuki (1983)
2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo
Gregory Maschek (2004)
L-S,R-buthionine sulfoximine: historical development and clinical issues.
H. Bailey (1998)
Production of large amounts of hydrogen peroxide by human tumor cells.
T. Szatrowski (1991)
Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas.
B. K. Mohanti (1996)
Enzymology of cancer cells (second of two parts).
G. Weber (1977)
Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines.
B. S. Dwarkanath (2001)
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction.
H. Ohkawa (1979)
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
T. Mosmann (1983)
Effects of 2deoxyD - glucose on glycolysis , proliferation kinetics and radiation response of human cancer cells
K. JainV. (1985)
Overexpression of fructose 2,6-bisphosphatase decreases glycolysis and delays cell cycle progression.
J. Pérez (2000)
Enzymology of cancer cells (first of two parts).
G. Weber (1977)
Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells.
V. K. Jain (1985)
Studies on respiration and glycolysis in transplanted hepatic tumors of the rat.
C. Lo (1968)
Antioxidant inhibitors for cancer
Q. Kong (1998)
Antioxidant nutrients and adriamycin toxicity, Toxicology
J. L. Quiles (2002)
Determination of glutathione and glutathione disulfide in biological samples.
M. Anderson (1985)
Reflectograph number six 8″ × 10″ black and white descriptive details appear mol. cell. biochem. 3, 223–226 (1974)
A. W. Bernheimer (2005)
Role of superoxide dismutase in cancer: a review.
L. Oberley (1979)
Regulation of prostate cancer cell division by glucose
G. Singh (1999)
Differential induction of 'metabolic genes' after mitogen stimulation and during normal cell cycle progression.
C. Bürger (1994)
Hypoglycemia-induced c-Jun Phosphorylation Is Mediated by c-Jun N-terminal Kinase 1 and Lyn Kinase in Drug-resistant Human Breast Carcinoma MCF-7/ADR Cells*
X. Liu (1997)
Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer
R. Moadel (2003)
Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism.
L. Wold (2005)
Glucose Deprivation‐Induced Oxidative Stress in Human Tumor Cells: A Fundamental Defect in Metabolism?
D. Spitz (2000)
Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-D-glucose.
Kelly K. Andringa (2006)
Response of rat gastrointestinal tract pentose cycle dehydrogenase systems to whole-body ionizing irradiation.
E. Kivy-Rosenberg (1971)
Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin.
S. Zhou (2001)
This paper is referenced by
A Review of Two Promising Radiosensitizers in Brain Metastases: Rrx-001 and 2-Deoxyglucose
B. Oronsky (2015)
Nanoparticles promise new methods to boost oncology outcomes in breast cancer.
J. Islamian (2015)
Possibilities to increase the effectiveness of doxorubicin in cancer cells killing
V. Hanušová (2011)
A study on drug delivery tracing with radiolabeled mesoporous hydroxyapatite nanoparticles conjugated with 2DG/DOX for breast tumor cells.
Mahdiyeh Shamsi (2018)
2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype
S. O'Neill (2019)
Emerging Metabolic Targets in the Therapy of Hematological Malignancies
Z. Leni (2013)
Application of (13) C isotope labeling using liquid chromatography mass spectrometry (LC-MS) to determining phosphate-containing metabolic incorporation.
S. K. Bhowmik (2015)
MLN4924 and 2DG combined treatment enhances the efficiency of radiotherapy in breast cancer cells
M. Oladghaffari (2017)
High Efficiency Apoptosis Induction in Breast Cancer Cell Lines by MLN4924/2DG Co-Treatment.
M. Oladghaffari (2015)
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents
B. Pająk (2019)
Combined Treatment with 2-Deoxy-D-Glucose and Doxorubicin Enhances the in Vitro Efficiency of Breast Cancer Radiotherapy.
J. Islamian (2015)
Breast cancer: early diagnosis and effective treatment by drug delivery tracing.
Mahdiyeh Shamsi (2017)
Targeted superparamagnetic nanoparticles coated with 2-deoxy-d-gloucose and doxorubicin more sensitize breast cancer cells to ionizing radiation.
J. Pirayesh Islamian (2017)
2-deoxy-D-Glucose Synergizes with Doxorubicin or L-Buthionine Sulfoximine to Reduce Adhesion and Migration of Breast Cancer Cells.
Ebtihal H. Mustafa (2015)
Enhanced Radiosensitivity and Chemosensitivity of Breast Cancer Cells by 2-Deoxy-D-Glucose in Combination Therapy
F. Aghaee (2012)